SIHUAN PHARM (00460.HK): Five New Specifications of Skin Booster Dongyan Approved for Marketing by NMPA

NewTimeSpace · 2026/10/05 18:51 · By Zeyu Wu

On 5 October 2026, SIHUAN PHARM (00460.HK) announced that five new specifications of the injectable sodium hyaluronate complex solution (product name: Dongyan), developed by its subsidiary Meiyan Space, have been approved for marketing by China's National Medical Products Administration, namely 0.75 mL, 1.25 mL, 1.75 mL, 2.25 mL and 2.75 mL per vial.

Key Highlights:

Dongyan was previously approved in seven specifications: 0.5 mL, 1.0 mL, 1.5 mL, 2.0 mL, 2.5 mL and 3.0 mL per vial, plus a 5 mL per box presentation containing two 2.5 mL vials.
Dongyan is China's first facial complex solution skin booster containing L-carnosine, with core ingredients including hyaluronic acid, L-carnosine, multiple amino acids and vitamin B2.

NewTimeSpace News: On 5 October 2026, the board of directors of Sihuan Pharmaceutical (stock code: 00460) announced that five new specifications of the injectable sodium hyaluronate complex solution (product name: Dongyan), independently developed by Meiyan Space Biotechnology (Jilin) Co., Ltd., a subsidiary of the Group, have been approved for marketing by China's National Medical Products Administration. The new specifications are 0.75 mL, 1.25 mL, 1.75 mL, 2.25 mL and 2.75 mL per vial.

The product was previously approved in seven specifications, namely 0.5 mL, 1.0 mL, 1.5 mL, 2.0 mL, 2.5 mL and 3.0 mL per vial, plus a 5 mL per box presentation containing two 2.5 mL vials; the additions fill the dosage gaps of the existing range. Dongyan is China's first facial complex solution skin booster containing L-carnosine, with core ingredients including hyaluronic acid, L-carnosine, multiple amino acids and vitamin B2, and is injected into the facial dermis. Meiyan Space's sales network covers more than 370 cities and over 9,000 medical aesthetics institutions in China.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

SIHUAN PHARM 00460.HK R&D Progress